54,465 Shares in Evolent Health, Inc. (NYSE:EVH) Acquired by Brevan Howard Capital Management LP

Brevan Howard Capital Management LP acquired a new position in Evolent Health, Inc. (NYSE:EVH - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 54,465 shares of the technology company's stock, valued at approximately $613,000.

Other hedge funds have also recently made changes to their positions in the company. Cadian Capital Management LP purchased a new position in shares of Evolent Health in the fourth quarter worth $58,781,000. Engaged Capital LLC increased its stake in shares of Evolent Health by 35.5% in the fourth quarter. Engaged Capital LLC now owns 5,404,768 shares of the technology company's stock worth $60,804,000 after buying an additional 1,415,300 shares during the period. Boston Partners increased its stake in shares of Evolent Health by 92.0% in the fourth quarter. Boston Partners now owns 2,444,006 shares of the technology company's stock worth $27,097,000 after buying an additional 1,171,304 shares during the period. Norges Bank purchased a new position in shares of Evolent Health in the fourth quarter worth $12,519,000. Finally, Barclays PLC increased its stake in shares of Evolent Health by 234.4% in the fourth quarter. Barclays PLC now owns 915,422 shares of the technology company's stock worth $10,298,000 after buying an additional 641,646 shares during the period.

Analyst Ratings Changes

A number of research analysts have issued reports on EVH shares. UBS Group boosted their price objective on shares of Evolent Health from $14.00 to $15.00 and gave the company a "buy" rating in a research report on Friday, May 9th. Royal Bank of Canada reduced their price objective on shares of Evolent Health from $20.00 to $17.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 14th. Needham & Company LLC reissued a "buy" rating and set a $15.00 price objective on shares of Evolent Health in a research report on Tuesday. JMP Securities reissued a "market outperform" rating and set a $13.00 price objective on shares of Evolent Health in a research report on Monday, April 28th. Finally, Truist Financial reduced their price objective on shares of Evolent Health from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, April 10th. One investment analyst has rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Evolent Health presently has an average rating of "Buy" and a consensus price target of $17.79.

Insider Buying and Selling

In other Evolent Health news, President Daniel Joseph Mccarthy bought 11,040 shares of the business's stock in a transaction that occurred on Thursday, March 6th. The stock was bought at an average cost of $9.01 per share, for a total transaction of $99,470.40. Following the completion of the transaction, the president now owns 389,004 shares of the company's stock, valued at $3,504,926.04. This represents a 2.92% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Brendan B. Springstubb bought 5,000 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The shares were acquired at an average price of $8.75 per share, with a total value of $43,750.00. Following the completion of the transaction, the director now directly owns 11,842 shares of the company's stock, valued at $103,617.50. This trade represents a 73.08% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 74,000 shares of company stock worth $666,315 in the last quarter. Corporate insiders own 1.40% of the company's stock.

Evolent Health Stock Down 1.9%

Evolent Health stock traded down $0.18 during mid-day trading on Wednesday, reaching $9.09. The stock had a trading volume of 933,938 shares, compared to its average volume of 2,393,693. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -11.09 and a beta of 1.04. The company has a 50-day moving average price of $9.62 and a two-hundred day moving average price of $11.35. Evolent Health, Inc. has a one year low of $8.35 and a one year high of $33.63. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04.

Evolent Health (NYSE:EVH - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The technology company reported $0.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.08 by ($0.02). The firm had revenue of $483.65 million during the quarter, compared to the consensus estimate of $460.15 million. Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. The business's revenue for the quarter was down 24.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.34 EPS. On average, analysts expect that Evolent Health, Inc. will post 0.08 EPS for the current fiscal year.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.